Covista Dirección
Dirección controles de criterios 2/4
El CEO de Covista es Steve Beard , nombrado en Sep 2021, tiene una permanencia de 4.67 años. compensación anual total es $17.24M, compuesta por 5.8% salario y 94.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.08% de las acciones de la empresa, por valor de $43.12M. La antigüedad media del equipo directivo y de la junta directiva es de 4.1 años y 7.6 años, respectivamente.
Información clave
Steve Beard
Chief Executive Officer (CEO)
US$17.2m
Compensación total
| Porcentaje del salario del CEO | 5.80% |
| Permanencia del CEO | 4.7yrs |
| Participación del CEO | 1.1% |
| Permanencia media de la dirección | 4.1yrs |
| Promedio de permanencia en la Junta Directiva | 7.6yrs |
Actualizaciones recientes de la dirección
Recent updates
Nueva narrativa • Apr 22
Health Care Workforce Shortages Will Pressure Capacity Expansion Yet Support Long Term Potential
Catalysts About Covista Covista is a health care education provider focused on training nurses, physicians, veterinarians and behavioral health professionals at scale. What are the underlying business or industry changes driving this perspective?
Nueva narrativa • Apr 08
Health Care Workforce Shortages And Digital Learning Will Support This Bullish Long Term Thesis
Catalysts About Covista Covista provides higher education programs focused on health care and related professional fields. What are the underlying business or industry changes driving this perspective?
Nueva narrativa • Mar 24
Health Care Workforce Shortages And Flexible Learning Will Support Stronger Long Term Outcomes
Catalysts About Covista Covista focuses on large scale health care education programs serving nursing, medical, veterinary and allied health students across the United States. What are the underlying business or industry changes driving this perspective?Seeking Alpha • Mar 13
Covista: A Mispriced Bet On The Healthcare Worker Shortage
Summary Covista is trading significantly below its intrinsic value despite short-term headwinds at Chamberlain University. All segments are growing revenue; Walden University’s 27% revenue and 13% enrollment growth offset Chamberlain’s 1% enrollment decline. Key risks include heavy reliance on Title IV funding and regulatory changes, though long-term healthcare demand and AI-driven career shifts support growth and limit risk. Read the full article on Seeking AlphaArtículo de análisis • Sep 27
With EPS Growth And More, Adtalem Global Education (NYSE:ATGE) Makes An Interesting Case
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Artículo de análisis • Aug 07
Adtalem Global Education (NYSE:ATGE) Has A Pretty Healthy Balance Sheet
NYSE:ATGE 1 Year Share Price vs Fair Value Explore Adtalem Global Education's Fair Values from the Community and select...Artículo de análisis • Jul 07
An Intrinsic Calculation For Adtalem Global Education Inc. (NYSE:ATGE) Suggests It's 44% Undervalued
Key Insights Adtalem Global Education's estimated fair value is US$221 based on 2 Stage Free Cash Flow to Equity...Artículo de análisis • May 13
There's Reason For Concern Over Adtalem Global Education Inc.'s (NYSE:ATGE) Massive 27% Price Jump
Adtalem Global Education Inc. ( NYSE:ATGE ) shareholders have had their patience rewarded with a 27% share price jump...Artículo de análisis • May 07
If EPS Growth Is Important To You, Adtalem Global Education (NYSE:ATGE) Presents An Opportunity
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Artículo de análisis • Apr 24
Is Adtalem Global Education (NYSE:ATGE) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Artículo de análisis • Mar 25
Adtalem Global Education Inc. (NYSE:ATGE) Shares Could Be 48% Below Their Intrinsic Value Estimate
Key Insights Adtalem Global Education's estimated fair value is US$198 based on 2 Stage Free Cash Flow to Equity...Artículo de análisis • Mar 11
Subdued Growth No Barrier To Adtalem Global Education Inc.'s (NYSE:ATGE) Price
With a median price-to-earnings (or "P/E") ratio of close to 17x in the United States, you could be forgiven for...Artículo de análisis • Feb 24
Is There Now An Opportunity In Adtalem Global Education Inc. (NYSE:ATGE)?
Adtalem Global Education Inc. ( NYSE:ATGE ), is not the largest company out there, but it saw a decent share price...Seeking Alpha • Feb 21
Adtalem Global Education: Surging On Registered Nurse Shortage
Summary Adtalem Global Education Inc.'s financial performance has surged with an underlying nationwide shortage of Registered Nurses and in mental health professionals. A shortage is expected to persist — Adtalem still looks to benefit from secular trends in an aging population, while the long-term performance depends on universities' ability to expand capacity. ATGE stock's surge already reflects a good mid-term earnings performance, making long-term growth required for significant returns. I estimate a fair value of $109.5. Read the full article on Seeking AlphaArtículo de análisis • Jan 21
With EPS Growth And More, Adtalem Global Education (NYSE:ATGE) Makes An Interesting Case
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Artículo de análisis • Dec 19
These 4 Measures Indicate That Adtalem Global Education (NYSE:ATGE) Is Using Debt Reasonably Well
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Dec 17
Adtalem Global Education Still Offers Competitive PEG Ratio And Substantial Share Buybacks
Summary The company has shown significant financial progress with improving EBIT and profit margins, indicating efficient cost management. Current valuation metrics suggest the company is rather cheaply priced, despite the good run in 2024. The future outlook remains positive, but investors should be aware of potential risks, such as the debt or future competitive threats from robotics. Read the full article on Seeking AlphaArtículo de análisis • Nov 26
Adtalem Global Education Inc.'s (NYSE:ATGE) Shares Climb 27% But Its Business Is Yet to Catch Up
Adtalem Global Education Inc. ( NYSE:ATGE ) shareholders would be excited to see that the share price has had a great...Artículo de análisis • Oct 31
Should You Think About Buying Adtalem Global Education Inc. (NYSE:ATGE) Now?
Adtalem Global Education Inc. ( NYSE:ATGE ), is not the largest company out there, but it led the NYSE gainers with a...Artículo de análisis • Oct 16
Should You Be Adding Adtalem Global Education (NYSE:ATGE) To Your Watchlist Today?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Seeking Alpha • Oct 04
Adtalem Global Education Faces Problems But Is Growing Steadily
Summary Adtalem Global Education focuses on medical and veterinary education, showing solid profitability and potential growth in a booming healthcare industry. Despite a current ratio below 1.0, ATGE maintains a reasonable price/book ratio and generates significant operating cash flow, indicating financial stability. Risks include reliance on government financial aid, maintaining accreditation, and ensuring student placements in healthcare jobs, which are crucial for sustaining reputation and revenue. With projected revenue growth and a forward P/E ratio of 13.12, Adtalem Global is a cautious buy, offering portfolio diversity in a growing sector. Read the full article on Seeking AlphaArtículo de análisis • Sep 16
Adtalem Global Education (NYSE:ATGE) Seems To Use Debt Quite Sensibly
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Artículo de análisis • Aug 29
Adtalem Global Education Inc.'s (NYSE:ATGE) Price In Tune With Earnings
With a price-to-earnings (or "P/E") ratio of 20.7x Adtalem Global Education Inc. ( NYSE:ATGE ) may be sending bearish...Artículo de análisis • Aug 14
We Think Adtalem Global Education's (NYSE:ATGE) Robust Earnings Are Conservative
Even though Adtalem Global Education Inc.'s ( NYSE:ATGE ) recent earnings release was robust, the market didn't seem to...Artículo de análisis • Jul 28
Should You Think About Buying Adtalem Global Education Inc. (NYSE:ATGE) Now?
While Adtalem Global Education Inc. ( NYSE:ATGE ) might not have the largest market cap around , it led the NYSE...Seeking Alpha • Jul 27
Adtalem Global Education: Still Undervalued After The Latest Rally
Summary Adtalem Global Education is set to report earnings on August 6th. The company specializes in healthcare education, with Chamberlain and Walden Universities under its wing, showing revenue growth post Walden acquisition. Financials show decent margins, but efficiency metrics trending down, with potential for top-line growth and margin expansion in the future. Read the full article on Seeking AlphaArtículo de análisis • Jul 12
Does Adtalem Global Education (NYSE:ATGE) Deserve A Spot On Your Watchlist?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Artículo de análisis • Jun 14
Adtalem Global Education (NYSE:ATGE) Has A Pretty Healthy Balance Sheet
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • May 19
Adtalem Global Education: A Leading Healthcare Educator In A Growing Industry
Summary ATGE has demonstrated robust revenue growth and strong profit margins over the past three years. ATGE's 3Q24 earnings showed year-over-year revenue growth of 11.8%, driven by growth in enrollment and tuition rates. The healthcare industry is facing significant labour shortages, which are expected to impact hospitals growth targets and outlook. ATGE plays a crucial role in training and providing healthcare professionals. Read the full article on Seeking AlphaAnálisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$250m |
| Dec 31 2025 | n/a | n/a | US$254m |
| Sep 30 2025 | n/a | n/a | US$247m |
| Jun 30 2025 | US$17m | US$1m | US$233m |
| Mar 31 2025 | n/a | n/a | US$229m |
| Dec 31 2024 | n/a | n/a | US$204m |
| Sep 30 2024 | n/a | n/a | US$172m |
| Jun 30 2024 | US$14m | US$987k | US$138m |
| Mar 31 2024 | n/a | n/a | US$111m |
| Dec 31 2023 | n/a | n/a | US$122m |
| Sep 30 2023 | n/a | n/a | US$108m |
| Jun 30 2023 | US$8m | US$950k | US$102m |
| Mar 31 2023 | n/a | n/a | US$79m |
| Dec 31 2022 | n/a | n/a | US$35m |
| Sep 30 2022 | n/a | n/a | US$47m |
| Jun 30 2022 | US$9m | US$828k | -US$36m |
| Mar 31 2022 | n/a | n/a | -US$35m |
| Dec 31 2021 | n/a | n/a | -US$15m |
| Sep 30 2021 | n/a | n/a | -US$26m |
| Jun 30 2021 | US$3m | US$600k | US$63m |
| Mar 31 2021 | n/a | n/a | US$139m |
| Dec 31 2020 | n/a | n/a | US$269m |
| Sep 30 2020 | n/a | n/a | US$246m |
| Jun 30 2020 | US$2m | US$598k | US$220m |
| Mar 31 2020 | n/a | n/a | US$208m |
| Dec 31 2019 | n/a | n/a | US$89m |
| Sep 30 2019 | n/a | n/a | US$130m |
| Jun 30 2019 | US$2m | US$536k | US$107m |
Compensación vs. Mercado: La compensación total de Steve($USD17.24M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD7.00M).
Compensación vs. Ingresos: La compensación de Steve ha aumentado más de un 20% en el último año.
CEO
Steve Beard (54 yo)
4.7yrs
Permanencia
US$17,244,988
Compensación
Mr. Stephen W. Beard, also known as Steve, J.D., serves as an Independent Director at Planet Fitness, Inc. since February 9, 2026. He served as Chief Operating Officer at Adtalem Global Education Inc. sinc...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Chairman | 4.7yrs | US$17.24m | 1.08% $ 43.1m | |
| Senior VP & CFO | 5.1yrs | US$2.02m | 0.13% $ 5.4m | |
| Senior VP of Institutional Support Services | 4.9yrs | US$1.65m | 0.096% $ 3.9m | |
| Chief Growth & Innovation Officer and President of Walden University | 4yrs | US$2.59m | 0.069% $ 2.8m | |
| President of Adtalem Medical & Veterinary | 2.1yrs | US$1.62m | 0.022% $ 871.5k | |
| VP & Chief Accounting Officer | 4.1yrs | sin datos | 0.0091% $ 365.2k | |
| Vice President of Investor Relations | no data | sin datos | sin datos | |
| Senior VP & Chief Human Resources Officer | 1.7yrs | sin datos | 0.0083% $ 331.1k | |
| Senior VP & Chief Corporate Affairs Officer | 1yr | sin datos | sin datos | |
| President of Chamberlain University | no data | sin datos | sin datos | |
| President of Chamberlain University | 7.8yrs | US$1.14m | 0.083% $ 3.3m | |
| Vice President of Treasury & Risk Management | no data | sin datos | sin datos |
4.1yrs
Permanencia media
55yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de CVSA se considera experimentado (4.1 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Chairman | 4.7yrs | US$17.24m | 1.08% $ 43.1m | |
| Director Emeritus | no data | US$108.37k | sin datos | |
| Director Emeritus | 12.5yrs | US$95.00k | sin datos | |
| Independent Director | 9.3yrs | US$250.17k | 0.026% $ 1.1m | |
| Lead Independent Director | 9.9yrs | US$251.42k | 0.41% $ 16.3m | |
| Independent Director | 6.1yrs | US$225.17k | 0.054% $ 2.2m | |
| Independent Director | 7.6yrs | US$237.67k | 0.020% $ 797.8k | |
| Director | 17.5yrs | US$273.17k | 0.13% $ 5.0m | |
| Independent Director | 6.1yrs | US$237.67k | 0.040% $ 1.6m | |
| Independent Director | 2.3yrs | US$225.17k | 0.0034% $ 134.3k | |
| Independent Director | 8yrs | US$237.67k | 0.047% $ 1.9m | |
| Independent Director | 3.9yrs | US$225.17k | 0.044% $ 1.8m |
7.6yrs
Permanencia media
66yo
Promedio de edad
Junta con experiencia: La junta directiva de CVSA se considera experimentada (7.6 años de antigüedad promedio).
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/31 02:19 |
| Precio de las acciones al final del día | 2026/05/29 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/06/30 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Covista Inc. está cubierta por 23 analistas. 4 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Gary Bisbee | Barclays |
| Alexander Paris | Barrington Research Associates, Inc. |
| Jeffrey Silber | BMO Capital Markets Equity Research |